SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: John O'Neill who wrote (18494)4/2/1998 11:16:00 AM
From: WTDEC  Respond to of 32384
 
JO, SRGN has a market cap of less than $10 million. LGND could take the cash deal from LLY and buy SRGN outright, for say $12 million. They would get Psoriasis, have a small interest in the CTCL drug plus cash left over, an higher royalty on another drug, etc. Imho, if LGND does anything at all with SRGN, it appears this is the way to go.

Regards,

Walter